date,title,source
Oct-26-18,Karyopharm Therapeutics Announces Management Change,GlobeNewswire
Oct-29-18,Karyopharm Therapeutics Announces Closing of Additional $22.5 Million of 3.00% Convertible Senior Notes Due 2025 Pursuant to Exercise in Full of Initial Purchasers Option,GlobeNewswire
Oct-31-18,Is Karyopharm Therapeutics Inc (NASDAQ:KPTI) Potentially Underrated?,Simply Wall St.
Nov-01-18,Karyopharm Announces Results of Clinical Studies Investigating Selinexor in Multiple Myeloma and Diffuse Large B-Cell Lymphoma to be Presented at the American Society of Hematology 2018 Annual Meeting,GlobeNewswire
Nov-01-18,"Karyopharm to Report Third Quarter 2018 Financial Results on November 8, 2018",GlobeNewswire
Nov-05-18,Karyopharm Therapeutics to Ring Nasdaq Closing Bell on November 6th,GlobeNewswire
Nov-07-18,Karyopharms Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma,GlobeNewswire
Nov-07-18,Karyopharm to Present at the Jefferies 2018 London Healthcare Conference,GlobeNewswire
Nov-08-18,"Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Lags Revenue Estimates",Zacks
Nov-08-18,Karyopharm Therapeutics: 3Q Earnings Snapshot,Associated Press
Nov-08-18,Karyopharm Reports Third Quarter 2018 Financial Results and Highlights Recent Company Progress,GlobeNewswire
Nov-13-18,"Report: Developing Opportunities within Evelo Biosciences, ADMA Biologics, Karyopharm Therapeutics, Pingtan Marine Enterprise, Rosetta Stone, and Williams Companies  Future Expectations, Projections Moving into 2018",GlobeNewswire
Dec-03-18,Karyopharm Reports Updated Selinexor Data from the Phase 2b STORM and Phase 1b/2 STOMP Studies in Relapsed/Refractory Multiple Myeloma at the American Society of Hematology 2018 Annual Meeting,GlobeNewswire
Dec-03-18,The 4 Healthcare Stocks To Watch On Monday,ACCESSWIRE
Dec-04-18,Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),GlobeNewswire
